A multicentric study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs co-administration of GSK's DTPa vaccine and Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children.

Trial Profile

A multicentric study to compare the immunogenicity, safety and reactogenicity of GSK Biologicals' DTPa-IPV vaccine vs co-administration of GSK's DTPa vaccine and Sanofi-Pasteurs' IPV vaccine at different injection sites, to healthy children.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Oct 2016

At a glance

  • Drugs DTaP poliovirus vaccine; DTaP vaccine; Poliovirus vaccine inactivated
  • Indications Diphtheria; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Sep 2008 Actual patient number changed from 450 to 452 as reported by ClinicalTrials.gov.
    • 31 Jul 2008 The actual completion date for this trial is now 1 Jan 2007.
    • 31 Jul 2008 Status changed from in progress to completed according to clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top